Tonix Pharmaceuticals Holding Q3 2026 earnings

TNXP · 2026-11-09 07:20 BMO ET · 8-K on SEC · 10-Q on SEC

Reported a net loss of $0.6 million for the quarter, with revenue of $2.3 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$2.3 million+$0.3 million+$0.4 millionEx. 99.1, Income Statement
EPS (GAAP)$(0.01)$(0.01)$(0.00)Ex. 99.1, Income Statement
EPS (adjusted)$(0.01)$(0.01)$(0.00)Ex. 99.1, Income Statement
Net income$(0.6) million$(0.7) million$(0.2) millionEx. 99.1, Income Statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 0.0%
  • Operating expenses $2.9 million (+4%)
  • One-offs in the quarter Non-cash stock-based compensation: $0.2 million; Non-cash interest expense: $0.1 million
  • Effective tax rate 0.0%
  • Non-GAAP bridge Adds back non-cash stock-based compensation and non-cash interest expense to arrive at adjusted EPS.

KPIs

MetricActualPrior quarterPrior yearChange
Cash and cash equivalents$11.6 million$11.2 million$11.2 million+$0.4 million
Total assets$436.1 million$435.9 million$435.9 million+$0.2 million
Total liabilities$435.5 million$435.3 million$435.3 million+$0.2 million

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue increased by $0.3 million YoY and $0.4 million QoQ.
  • EPS story Net loss per share remained flat YoY and QoQ.
  • One-off check Non-cash stock-based compensation of $0.2 million and non-cash interest expense of $0.1 million are one-time items.

The good

  • Cash and cash equivalents increased by $0.4 million to $11.6 million.

The bad

  • Net loss of $0.6 million for the quarter.
  • Operating expenses increased by 4% YoY to $2.9 million.

The ugly

  • none

Open questions

  • The release does not disclose the specific revenue drivers or product sales contributing to the $2.3 million revenue.
  • The release does not provide a reconciliation of the adjusted EPS calculation.
Full release

Tonix Pharmaceuticals Holding (TNXP) earnings release, November 9, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) · Form 8-K, Item 2.02 · Filed · SEC filing

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 ex99-01.htm Additional exhibits

Financial statements

Income Statement

From the 10-Q · Three Months Ended September 30, — (unaudited) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
REVENUE:
Product revenue, net17,2343,29037,6567,717
COSTS AND EXPENSES:
Cost of sales1,2521,3673,5335,582
Research and development25,8249,28963,45427,545
Selling, general and administrative45,59025,701110,17352,007
Total operating expenses72,66636,357177,16085,134
Operating loss-55,432-33,067-139,504-77,417
Contract income6669821,2662,941
Loss on extinguishment of debt-2,092
Interest income, net1,3621,2314,1402,713
Other income (expense), net75-1,15623-3,256
Net loss available to common stockholders-53,329-32,010-134,075-77,111
Net loss per common share, basic and diluted-2.89-3.59-8.24-10.42
Weighted average common shares outstanding, basic and diluted18,440,7738,922,79216,278,3837,403,400

Balance Sheet

From the 10-Q · September 30, — (In Thousands, Except Par Value and Share Amounts) (unaudited)

September 30, – 2026December 31, – 2025
Current assets:
Cash and cash equivalents162,793207,637
Accounts receivable, net14,5996,271
Inventory4,4786,013
Prepaid expenses and other current assets10,2658,955
Total current assets192,135228,876
Property and equipment, net44,88844,456
Operating lease right-of-use assets1,2481,544
Other non-current assets4,1552,295
Total assets242,426277,171
Current liabilities:
Accounts payable17,0628,114
Accrued expenses and other current liabilities24,62622,598
Lease liability, short term338125
Total current liabilities42,02630,837
Lease liability, long term9151,184
Total liabilities42,94132,021
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 19,150,163 and 12,788,069 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively, and 5,883 shares to be issued as of December 31, 20251913
Additional paid-in capital1,188,6471,100,141
Accumulated deficit-988,790-854,715
Accumulated other comprehensive loss-391-289
Total stockholders’ equity199,485245,150
Total liabilities and stockholders’ equity242,426277,171

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (unaudited) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss-134,075-77,111
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,8171,437
Loss on note1,159
Loss on extinguishment of debt2,092
Bad debt31
Issuance costs of derivative instruments1,837
Inventory write-off1,318
Amortization of debt discount65
Stock-based compensation6,5194,228
Changes in operating assets and liabilities:
Other non-current assets-2,169
Accounts receivable-8,328170
Inventory, current and non-current621,362
Prepaid expenses and other current assets-1,311-2,159
Accounts payable9,5813,732
Lease liabilities and ROU asset, net241-18
Accrued expenses and other current liabilities2,0281,663
Net cash used in operating activities-125,635-60,194
CASH FLOWS FROM INVESTING ACTIVITIES:
Issuance of note-2,012
Purchase of property and equipment-2,882-1,495
Net cash used in investing activities-2,882-3,507
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of common stock-5,949
Proceeds from exercise of options52
Proceeds from ESPP227
Payment of term loan-9,650
Proceeds, net of $2,621 and $5,750 expenses, from sale of common stock and warrants81,714170,986
Net cash provided by financing activities81,993155,387
Effect of currency rate change on cash-102-17

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Tonix Pharmaceuticals Holding earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.